Related Topics News - Drugs

     
 < Previous page   Title only   |   Print    Next page > 
     
《大行》花旗微降國藥目標價至22.6元 首季業績大致符預期

2026-04-28T  
《大行》高盛降國藥控股目標價至19.07元 料未來數季收入逐步復甦

2026-04-28T  
《大行》里昂升國藥控股目標價至25元 續予「跑贏大市」評級

2026-04-28T  
《業績》白雲山首季淨利潤17.84億人民幣 倒退2.1%

2026-04-27T  
康哲藥業就兩款已上市原研藥簽訂獨家商業化與供應協議

2026-04-27T  
《大行》高盛:內地CDMO板塊穩健 看好藥明康德凱萊英等

2026-04-27T  
《藍籌》國藥控股首季純利14.1億人幣 按年跌3%

2026-04-27T  
康哲藥業新藥MG-K10上市許可申請獲受理

2026-04-23T  
國藥控股附屬國藥股份首季賺4.74億人民幣 增長3.3%

2026-04-22T  
聯邦制藥度普利尤單抗注射液獲臨床試驗默示許可

2026-04-22T  
 < Previous page    Next page > 

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.